BioCentury
ARTICLE | Clinical News

Amgen, UCB again seeking FDA nod for osteoporosis mAb

July 20, 2018 5:11 PM UTC

A year after receiving a complete response letter for Evenity romosozumab, Amgen Inc. (NASDAQ:AMGN) and UCB S.A. (Euronext:UCB) have resubmitted a BLA to FDA for the mAb to treat osteoporosis.

During Evenity's initial FDA review in 2017, the partners revealed a previously unseen cardiovascular safety signal in the Phase III ARCH study. The BLA did not include ARCH's data (see "CV Signal in Osteoporosis Trial Sinks UCB, Amgen Shares")...

BCIQ Company Profiles

Amgen Inc.

UCB S.A.